Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02370706
Other study ID # CPIM447X2104C
Secondary ID 2014-003801-14
Status Completed
Phase Phase 1
First received
Last updated
Start date May 21, 2015
Est. completion date November 9, 2020

Study information

Verified date February 2022
Source Novartis
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a phase Ib study with the primary purpose is to estimate the MTD and/or RDE for the triple combination of PIM447, formerly LGH447, plus ruxolitinib and LEE011 as well as for the doublets, PIM447 plus ruxolitinib, and LEE011 plus ruxolitinib, in patients with myelofibrosis (MF). Each regimen will be assessed for safety, tolerability, pharmacokinetics (PK) and pharmacodynamic effects, and preliminary anti-myelofibrosis activity, including changes in spleen volume, JAK2V617F allele burden, and hematologic response.


Recruitment information / eligibility

Status Completed
Enrollment 15
Est. completion date November 9, 2020
Est. primary completion date November 9, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2. - Patient must be diagnosed with JAK2V617F-positive primary or secondary MF. - Dose-escalation and Expansion parts: Patients with a < 35% reduction in spleen volume by MRI/CT or < 50% reduction in spleen size by physical exam, with or without corresponding symptomatic improvement, after at least 6 months of treatment with single agent ruxolitinib at an optimal dose level in line with the label recommendations. Expansion parts only: Ruxolitinib-naive patients and patients who have been previously treated with single agent ruxolitinib and are relapsed and/or refractory. - Patients must have splenomegaly measuring at least 5 cm by MRI at baseline. - Have adequate bone marrow function: - Platelets = 100,000 mm3 without the assistance of growth factors or platelet transfusions - Absolute Neutrophil Count (ANC) = 1500/mm3 without growth factor support within 7 days prior to testing - Hemoglobin = 9 g/dL. Exclusion Criteria: - Systemic antineoplastic therapy (including unconjugated therapeutic antibodies, toxin immunoconjugates, and alpha-interferon) or any experimental therapy within 14 days or 5 half-lives, whichever is shorter, before the first dose of study treatment - Major surgery within 2 weeks before the first dose of either study drug. - Patients who have had splenic irradiation within 2 weeks prior to Screening or prior splenectomy. - Patients with AML, MDS, or peripheral blasts = 10 % - Prior autologous or allogeneic stem cell transplant at any time. - Patients who are currently receiving treatment with a prohibited medication that cannot be discontinued at least one week prior to the start of treatment: - substrates of CYP3A4/5, CYP2B6 or CYP2D6 that have a narrow therapeutic window - strong inhibitors of CYP3A4/5 or CYP2D6 - potent inducers of CYP3A4/5 or CYP2D6 - Serum total bilirubin > 1.5 x upper limit of normal (ULN) except in patients with Gilbert's syndrome who are excluded if the total bilirubin is > 3.0 x ULN or direct bilirubin > 1.5 x ULN, or aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) or ALT (SGPT) > 3 x ULN, except in patients with MF involvement of the liver who are excluded if AST or ALT > 5 x ULN. - Serum creatinine > 1.5 x ULN or calculated creatinine clearance < 60 ml/min according to Cockcroft-Gault equation - Electrolyte abnormalities CTCAE grade = 2 (e.g. serum potassium, magnesium and calcium) unless they can be repleted during screening and are deemed not clinically significant by the Investigator.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
PIM447
pan-pim inhibitor
Ruxolitinib
JAK1/JAK2 inhibitor
LEE011
CDK4/6 inhibitor

Locations

Country Name City State
Australia Novartis Investigative Site VIC Melbourne
Canada Novartis Investigative Site Toronto Ontario
France Novartis Investigative Site Villejuif Cedex
Germany Novartis Investigative Site Mainz
Germany Novartis Investigative Site Ulm
Italy Novartis Investigative Site Firenze FI
Netherlands Novartis Investigative Site Rotterdam
Singapore Novartis Investigative Site Singapore
United Kingdom Novartis Investigative Site London

Sponsors (1)

Lead Sponsor Collaborator
Novartis Pharmaceuticals

Countries where clinical trial is conducted

Australia,  Canada,  France,  Germany,  Italy,  Netherlands,  Singapore,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence of dose limiting toxicities during the first cycle of study treatment To estimate the maximum tolerated dose and/or recommended dose for expansion for each of the following three treatment arms in patients with myelofibrosis (MF): PIM447 plus ruxolitinib (doublet), LEE011 plus ruxolitinib (doublet), PIM447 plus ruxolitinib and LEE 011 (triple combination). Cycle 1 (28 days)
Secondary Number of participants with adverse events/serious adverse events Frequency and severity of adverse events (AEs), serious AEs (SAEs), changes in laboratory values, and electrocardiograms (ECGs), as a measure of safety and tolerability. Assessments consisted of recording all adverse events (AEs) and serious adverse events (SAEs), the regular monitoring of hematology, blood chemistry, urinalysis, and coagulation parameters, as well as electrocardiograms. Approximately 27 months (end of study)
Secondary Proportion of patients achieving = 35% reduction in spleen volume by magnetic resonance imaging (MRI) at Week 24 To assess preliminary anti-myelofibrosis activity of PIM447 plus ruxolitinib, LEE011 plus ruxolitinib, and the triple combination PIM447 plus ruxolitinib and LEE011. 24 weeks
Secondary Changes in ratio of mutant to wild type JAK2 alleles (i.e. allele burden) To assess preliminary anti-myelofibrosis activity of PIM447 plus ruxolitinib, LEE011 plus ruxolitinib, and the triple combination PIM447 plus ruxolitinib and LEE011. Approximately 27 months (end of study)
Secondary Change in platelets, neutrophils, and hemoglobin To assess preliminary anti-myelofibrosis activity of PIM447 plus ruxolitinib, LEE011 plus ruxolitinib, and the triple combination PIM447 plus ruxolitinib and LEE011. Approximately 27 months (end of study)
Secondary Change in bone marrow fibrosis and histomorphology To assess preliminary anti-myelofibrosis activity of PIM447 plus ruxolitinib, LEE011 plus ruxolitinib, and the triple combination PIM447 plus ruxolitinib and LEE011. Approximately 27 months (end of study)
Secondary Determine single and multiple dose pharmacokinetics (PK) profiles Plasma concentration-time profiles of PIM447, ruxolitinib, and LEE011. PK parameters, including but not limited to Cmax, AUCinf, AUClast, AUCtau, T½, Tmax, accumulation ratio (Racc), CL/F, and Vz/F Approximately 12 months
Secondary Change in spleen volume as measured by MRI from baseline To assess preliminary anti-myelofibrosis activity of PIM447 plus ruxolitinib, LEE011 plus ruxolitinib, and the triple combination PIM447 plus ruxolitinib and LEE011. Approximately 27 months (end of study)
See also
  Status Clinical Trial Phase
Completed NCT02916979 - Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG Phase 1
Not yet recruiting NCT06345495 - High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly Phase 2
Terminated NCT04866056 - Jaktinib and Azacitidine In Treating Patients With MDS With MF or MDS/MPN With MF. Phase 1/Phase 2
Completed NCT02784496 - Long-Term Side Effects of Ruxolitinib in Treating Patients With Myelofibrosis Phase 2
Completed NCT00069680 - Genetic Analysis of Gray Platelet Syndrome
Active, not recruiting NCT04097821 - Platform Study of Novel Ruxolitinib Combinations in Myelofibrosis Patients Phase 1/Phase 2
Active, not recruiting NCT03289910 - Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia Phase 2
Completed NCT04666025 - SARS-CoV-2 Donor-Recipient Immunity Transfer
Not yet recruiting NCT06397313 - RVU120 in Patients With Intermediate or High-risk, Primary or Secondary Myelofibrosis Phase 2
Not yet recruiting NCT06024915 - A Study to Evaluate Drug-Drug Interaction of TQ05105 Tablets Phase 1
Terminated NCT02877082 - Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients Phase 2
Completed NCT02910258 - Interferon-pegyle α2a Efficiency and Tolerance in Myelofibrosis
Completed NCT00997386 - Reduced Intensity Allogeneic PBSCT to Treat Hematologic Malignancies and Hematopoietic Failure States Phase 2
Completed NCT00975975 - Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent Graft-Versus_Host Disease (GVHD) After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer Phase 2
Completed NCT00666549 - Research Tissue Bank
Terminated NCT00393380 - Study of Parathyroid Hormone Following Sequential Cord Blood Transplantation From an Unrelated Donor Phase 2
Terminated NCT00522990 - Study to Assess the Safety of Escalating Doses of AT9283, in Patients With Leukemias Phase 1/Phase 2
Completed NCT00606437 - Total Body Irradiation With Fludarabine Followed by Combined Umbilical Cord Blood (UCB) Transplants Phase 1
Active, not recruiting NCT03952039 - An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib Phase 3
Not yet recruiting NCT04709458 - Safety and Early Efficacy Study of TBX-2400 in Patients With AML or Myelofibrosis Phase 1